High-dose escitalopram for the treatment of obsessive–compulsive disorder
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The aim of this study was to evaluate the efficacy and tolerability of high-dose escitalopram in patients suffering from obsessive-compulsive disorder (OCD). In an open-label, 16-week prospective study, patients with OCD received escitalopram at a dose of 20 mg/day for 3 weeks, after a 1-week titration at 10 mg/day. Patients who did not achieve a > or =25% reduction from baseline in the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score during these 4 weeks were continued on higher doses of escitalopram (maximum 50 mg/day) for 12 weeks. The primary efficacy measure of OCD symptoms was change from baseline in the Y-BOCS score. Overall, 67 patients (33 women, 34 men) with a mean Y-BOCS score of 29.6 entered the study. After 4 weeks of standard-dose escitalopram treatment, one patient discontinued owing to pregnancy, and two patients achieved a reduction in Y-BOCS > or =25%. Consequently, 64 patients were eligible to receive high-dose escitalopram (mean dose, 33.8 mg/day at endpoint). At endpoint, high-dose escitalopram had significantly improved the OCD symptoms (Y-BOCS score) and all the other efficacy measures (P<0.001), compared with baseline. Escitalopram was also well tolerated, with no discontinuations during the 12-week high-dose phase. The only reported adverse drug reactions were dry mouth (n=8, 12.1%) and decreased sexual desire (n=21, 31.8%). Preliminary investigation shows that high-dose escitalopram is an efficacious and well tolerated treatment for patients suffering from severe OCD. Randomized, blinded studies are needed to reinforce these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evidence-based pharmacotherapy of obsessive-compulsive disorder
Fineberg, N. A., Brown, A., Reghunandanan, S., & Pampaloni, I. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001829 · Cited by 336
Overbeek, T., Schruers, K., Vermetten, E., & Griez, E. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1204 · Cited by 196
Mechanisms of action of current and potential pharmacotherapies of obsessive–compulsive disorder
El Mansari, M., & Blier, P. (2006) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.11.005 · Cited by 142 · cited 1×
“…(inducing a greater degree of serotonin reuptake inhibition) are frequently necessary to achieve a response in OCD (Heyman et al., 2006; El Mansari and Blier, 2006): SSRIs demonstrate a dose-dependent therapeutic effect (Tollefson et al., 1994; Montgomery et al., 2001; Hollander et al.,…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Escitalopram [705-709] 1 Phenelzine [737,738] 2*”
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Fineberg, N. A., Reghunandanan, S., Simpson, H. B., Phillips, K. A., Richter, M. A., Matthews, K., Stein, D. J., Sareen, J., Brown, A., & Sookman, D. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.003 · Cited by 150
Cognitive behavioral therapy is effective in misophonia: An open trial
Schröder, A. E., Vulink, N. C., van Loon, A. J., & Denys, D. A. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.04.017 · Cited by 139
D'Urso, G., Brunoni, A. R., Mazzaferro, M. P., Anastasia, A., de Bartolomeis, A., & Mantovani, A. (2016) · Depression and Anxiety · doi:10.1002/da.22578 · Cited by 107
Metadata
- Authors
- Rabinowitz, I., Baruch, Y., & Barak, Y.
- Venue
- International Clinical Psychopharmacology
- Published
- 2008-01
- Volume
- 23
- Issue
- 1
- Pages
- 49-53
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W1973127200
- Cited by
- 70
- References
- 3
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High-dose escitalopram for the treatment of obsessive–compulsive disorder. https://app.cochat.ai/papers/10.1097/yic.0b013e3282f0f0c5
- The paper
- Rabinowitz, I., Baruch, Y., & Barak, Y. (2008). High-dose escitalopram for the treatment of obsessive–compulsive disorder. International Clinical Psychopharmacology. https://doi.org/10.1097/yic.0b013e3282f0f0c5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.